Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck

Internal and External Triggering Mechanism of “Smart” Nanoparticle-Based DDSs in Targeted Tumor Therapy

(2018) Xian-ling Qiana et al.   CURRENT PHARMACEUTICAL DESIGN

Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives

(2018) Bachar Samra et al.   JOURNAL OF INVESTIGATIVE MEDICINE

A phase 2, multicenter study to evaluate the efficacy and safety of autologous tumor infiltrating lymphocytes (LN-145) for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC).

(2018) Rom S. Leidner et al.   JOURNAL OF CLINICAL ONCOLOGY

Exosomes: natural nanoparticles as bio shuttles for RNAi delivery

(2018) Saber Ghazizadeh Darband et al.   JOURNAL OF CONTROLLED RELEASE

Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature

(2015) Omar F. Khan et al.   NANO LETTERS

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

(2015) Jonathan E. Zuckerman et al.   NATURE REVIEWS DRUG DISCOVERY

In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight

(2014) James E. Dahlman et al.   Nature Nanotechnology

In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase

(2012) Eric J. Sorscher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems

(2012) Andrea Masotti   Recent Patents on Nanotechnology

Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase

(2011) W B Parker et al.   CANCER GENE THERAPY

Armed and targeted measles virus for chemovirotherapy of pancreatic cancer

(2011) S Bossow et al.   CANCER GENE THERAPY

Nucleobase Transport by Human Equilibrative Nucleoside Transporter 1 (hENT1)

(2011) Sylvia Y. M. Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy

(2011) Xinhua Xie et al.   JOURNAL OF GENE MEDICINE

Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene

(2010) C-K Tai et al.   CANCER GENE THERAPY

Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions

(2010) H J T van Zeeburg et al.   GENE THERAPY

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

(2008) Akin Akinc et al.   NATURE BIOTECHNOLOGY